Manipulating 'Death Fold' Proteins to Influence Cell Fate in Disease

Scientists are delving into the mechanisms of 'death fold' proteins to unravel the reasons behind premature cell death in some instances and delayed demise in others.

In conditions like Alzheimer’s, neurons perish prematurely, whereas in cancer, malignant cells persist far too long.

These conditions both disrupt the cellular process known as programmed cell death, altering when and how cells choose to end their lifecycle.

"Despite its grim connotation, programmed cell death is vital for maintaining health," explains an expert, a veteran in this field at St. Jude Children’s Research Hospital, Memphis.

The potential to prolong the lifespan of neural cells could significantly benefit those battling Alzheimer’s, Parkinson’s, or ALS (Lou Gehrig’s disease), whereas facilitating earlier death of cancer cells could aid cancer patients.

Researchers are actively seeking therapies to adjust how cells opt to undergo self-destruction, according to Green.

At the Stowers Institute for Medical Research in Kansas City, there is ongoing research on immune cells that self-destruct upon encountering harmful molecules.

"These cells must identify [the threat] amidst countless complex molecules," he notes, "and then promptly initiate their own demise."

This mechanism is likened to a soldier sacrificing themselves on a grenade to protect others.

The focus of Halfmann's research team is on specific intracellular proteins that set off this self-destruction sequence.

On detecting molecules linked to viruses or pathogens, these proteins undergo structural changes and trigger a self-destruction cascade.

The proteins begin to fold and aggregate, forming what's called a 'polymer,' initiating a polymerization cascade that eventually leads to cell death.

Although it is known that this process requires considerable energy, pinpointing the precise energy source was previously challenging.

The team speculated it might function similarly to hand warmers, which generate heat as they change from liquid to crystalline states.

The initial small crystal formation, triggered by pressing a metal disk, triggers rapid expansion into larger crystals, releasing significant energy.

"This is exactly the reaction we hypothesized for these proteins," says Halfmann.

His team published findings supporting this hypothesis in a scientific journal.

Halfmann expressed concern over the notion of cells perpetually poised to self-destruct spontaneously.

"Such a precarious existence," he reflects, "with every cell momentarily risking unexpected death."

This self-destruction is desirable in cancerous or virus-infected cells. Yet, Halfmann suspects it may lead to unnecessary neuronal death in Alzheimer’s.

A characteristic of Alzheimer’s disease is a protein known as amyloid, which becomes misfolded.

"This amyloid, for reasons not fully understood, leads to neuron death," he states.

Misfolded amyloid proteins, resembling death fold proteins, accumulate and create crystal-like deposits.

Thus, Halfmann is exploring ways to interfere with these crystal formations, akin to using antifreeze to prevent water from solidifying.

Biotech companies, meanwhile, are targeting different stages of this process, attempting to impede communication pathways crucial for cell demise.

Several companies are fervently investigating how to disrupt specific pathways, especially those engaging the death fold proteins that Halfmann's group examines.

These pathways contribute to inflammation and neuronal demise in neurodegenerative diseases such as Alzheimer’s.

These firms are developing antisense drugs to stop the synthesis of particular proteins, including death fold proteins, offering hope in combating aging-related and inflammatory diseases.

By fundamentally altering how cells determine when to die, these innovations could significantly impact disease treatment, states Green.